Pulmonx Corp - Asset Resilience Ratio
Pulmonx Corp (LUNG) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Pulmonx Corp debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Pulmonx Corp's Asset Resilience Ratio has changed over time. See net assets of Pulmonx Corp for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Pulmonx Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Pulmonx Corp.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Pulmonx Corp maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Pulmonx Corp Industry Peers by Asset Resilience Ratio
Compare Pulmonx Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 3.37% |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607 |
Medical Devices | 16.21% |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS |
Medical Devices | 54.67% |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO |
Medical Devices | 30.97% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
|
Aligned Genetics Inc
KQ:238120 |
Medical Devices | 2.22% |
|
Heramed Ltd
AU:HMD |
Medical Devices | 0.83% |
|
Acarix A/S
ST:ACARIX |
Medical Devices | 37.81% |
Annual Asset Resilience Ratio for Pulmonx Corp (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Pulmonx Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 18.78% | $30.58 Million | $162.85 Million | -0.10pp |
| 2023-12-31 | 18.87% | $33.55 Million | $177.78 Million | -1.47pp |
| 2022-12-31 | 20.34% | $39.40 Million | $193.68 Million | +6.92pp |
| 2021-12-31 | 13.42% | $31.56 Million | $235.17 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $263.71 Million | -- |
| 2019-12-31 | 25.37% | $13.58 Million | $53.53 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $15.01 Million | -- |
About Pulmonx Corp
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ven… Read more